Meiji Seika Pharma to Present Global Phase III Results for OP0595, a Novel β-Lactamase Inhibitor Combating AMR, at IDWeek 2025

Meiji Holdings Co. Ltd. published this content on September 19, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 19, 2025 at 01:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]